1. Home
  2. GGR vs PMVP Comparison

GGR vs PMVP Comparison

Compare GGR & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gogoro Inc.

GGR

Gogoro Inc.

HOLD

Current Price

$3.90

Market Cap

83.3M

ML Signal

HOLD

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

HOLD

Current Price

$1.39

Market Cap

76.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGR
PMVP
Founded
2011
2013
Country
Taiwan
United States
Employees
1416
N/A
Industry
Auto Manufacturing
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.3M
76.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
GGR
PMVP
Price
$3.90
$1.39
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.0K
392.4K
Earning Date
05-21-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.07
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.83
52 Week High
$6.21
$1.88

Technical Indicators

Market Signals
Indicator
GGR
PMVP
Relative Strength Index (RSI) 44.08 48.85
Support Level $3.63 $1.37
Resistance Level $4.25 $1.50
Average True Range (ATR) 0.20 0.05
MACD -0.05 -0.00
Stochastic Oscillator 25.00 18.75

Price Performance

Historical Comparison
GGR
PMVP

About GGR Gogoro Inc.

Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: